Table 1.
Baseline characteristics of enrolled patients.
| Characteristics | Total (n=119) |
HBV reactivation (n=12) |
Non-reactivation (n=107) |
P value |
|---|---|---|---|---|
| Age, years ≥60 <60 |
57(19-82) 46(38.7%) 73(61.3%) |
53.5(19-72) 5(41.7%) 7(58.3%) |
57(24-82) 41(38.3%) 66(61.7%) |
0.455a
1.000b |
| Gender Male Female |
109(91.6%) 10(8.4%) |
11(91.7%) 1(8.3%) |
98(91.6%) 9(8.4%) |
1.000b |
| History of alcoholism Yes No |
30(25.2%) 89(74.8%) |
5(41.7%) 7(58.3%) |
25(23.4%) 82(76.6%) |
0.301b |
| Antiviral prophylaxis Yes No |
95(79.8%) 24(20.2%) |
4(33.3%) 8(66.7%) |
91(85.0%) 16(15.0%) |
<0.001b |
| HBsAg Seropositive Seronegative |
113(95.0%) 6(5.0%) |
10(83.3%) 2(16.7%) |
103(96.3%) 4(3.7%) |
0.112c |
| HBeAg Seropositive Seronegative |
15(12.6%) 104(87.4%) |
2(16.7%) 10(83.3%) |
13(12.1%) 94(87.9%) |
1.000b |
| Child-pugh A B |
104(87.4%) 15(12.6%) |
10(83.3%) 2(16.7%) |
94(87.9%) 13(12.1%) |
1.000b |
| BCLC B C |
75(63.0%) 44(37.0%) |
8(66.7%) 4(33.3%) |
67(62.6%) 40(37.4%) |
1.000b |
| HBV DNA, IU/mL | ||||
| Undetectable Detectable >2000 ≤2000 Median(range) |
62(52.1%) 57(47.9%) 30(25.2%) 89(74.8%) 0 (0-3.89×106) |
11(91.7%) 1(8.3%) 0(0%) 12(100%) 0 (0-173) |
51(47.7%) 56(52.3%) 30(28.0%) 77(72.0%) 33 (0-3.89×106) |
0.004b
0.077b 0.004d |
| ALT, U/L | 34 (8-123) |
38.5 (14-110) |
34 (8-123) |
0.534d |
| ALT>1 ULN ALT ≤ 1 ULN ALT>2 ULN ALT ≤ 2 ULN |
37(31.1%) 82(68.9%) 6(5.0%) 113(95.0%) |
4(33.3%) 8(66.7%) 1(8.3%) 11(91.7%) |
33(30.8%) 74(69.2%) 5(4.7%) 102(95.3%) |
1.000b
0.479c |
| AST, U/L | 41 (15-225) |
54 (17-113) |
40 (15-225) |
0.691d |
| TBil, μmol/L | 16.8 (2.8-78.2) |
16.35 (9.7-54) |
17.1 (2.8-78.2) |
0.678d |
| ALB, g/L | 39.4 (25.1-48.9) |
40.85 (31.4-48.1) |
39.3 (25.1-48.9) |
0.317a |
| AFP, ng/mL AFP≥200 AFP<200 |
200.9 (1-164935) 60(50.4%) 59(49.6%) |
314.165 (1.75-21685) 7(58.3%) 5(41.7%) |
180.7 (1-164935) 53(49.5%) 54(50.5%) |
0.737d
0.563b |
| WBC, ×109/L | 5 (1.4-32) |
5.5 (2.8-10.1) |
5 (1.4-32) |
0.665d |
| NLR >2.5 ≤2.5 |
77(64.7%) 42(35.3%) |
5(41.7%) 7(58.3) |
72(67.3%) 35(32.7%) |
0.149b |
| PLT, ×109/L | 115 (19-493) |
131.5 (22-493) |
115 (19-345) |
0.336d |
AFP, alpha fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; NLR, neutrophil to lymphocyte ratio; TBil, total bilirubin; ULN, upper limit of normal; WBC, leukocyte; PLT, platelet.
a: T test.
b: χ2 test.
c: Fisher exact test.
d: Mann-Whitney U test.